红花黄色素联合阿加曲班对急性脑梗死患者血液流变学及预后的改善作用(1)
[摘要] 目的 探討对急性脑梗死患者联用红花黄色素与阿加曲班治疗后血液流变学的效果，并观察预后成效。 方法方便选取山东省济南市第三人民医院2016年1月—2017年9月收治的88例急性脑梗死患者，随机分为常规组(44例，常规西药+阿加曲班)、联合组(44例，常规西药+阿加曲班+红花黄色素)。对比血液流变学指标变化，神经功能缺损评分(NIHSS)、日常生活能力评分(BI)变化，评价预后成效。 结果 治疗后2组全血高切黏度、全血低切黏度、纤维蛋白原均显著降低(P<0.05)，且治疗后联合组全血高切黏度、全血低切黏度、纤维蛋白原均低于常规组[(5.06±0.31)mPa·svs(6.10±0.33)mPa·s；(7.40±0.39)mPa·svs(9.12±0.42)mPa·s；(3.11±0.68)g/L vs(4.30±0.75)g/L](t=15.236、19.906、7.797，P<0.05)；治疗后2组NIHSS均显著降低(P<0.05)，BI评分均显著升高(P<0.05)，且治疗后联合组NIHSS评分低于常规组(6.17±0.99)分vs(10.45±1.02)分t=19.973，P<0.05)，BI评分高于常规组[(68.96±5.12)分vs(62.75±5.09)分](t=5.706，P<0.05)；联合组预后良好率为88.64%，明显低于常规组的70.45%(χ2=4.470，P<0.05)。 结论 对急性脑梗死患者联合采用红花黄色素和阿加曲班能够显著改善血液流变学指标、神经功能和日常生活能力，提升预后成效。
[关键词] 红花黄色素；阿加曲班；急性脑梗死；血液流变学；预后
[中图分类号] R743.3 [文献标识码] A [文章编号] 1674-0742(2018)08(a)-0113-03
Effect of Safflower Yellow Combined with Argatroban on Hemorheology and Prognosis of Patients with Acute Cerebral Infarction
CAO Shi-xia
Department of Pharmacy Outpatient， the Third People's Hospital of Jinan， Jinan， Shandong Province， 250132 China
[Abstract] Objective To investigate the effect of combined use of safflor yellow and argatroban on hemorheology in patients with acute cerebral infarction， and to observe the effect of prognosis. Methods Convenient select 88 patients with acute cerebral infarction admitted to the Third People's Hospital of Jinan City from January 2016 to September 2017 were randomly divided into conventional group (44 cases， conventional western medicine plus argatroban) and combination group (44 cases)， conventional western medicine + Argatroban + safflower yellow pigment. The changes in hemorheological indexes， changes in neurological deficit scores (NIHSS)， and daily living ability scores (BI) were compared to evaluate the prognosis. Results After treatment， the whole blood hyperviscosity， whole blood hypoviscosity， and fibrinogen were significantly decreased in the two groups (P<0.05). After treatment， the whole blood hyperviscosity， whole blood low-cut viscosity， and fibrinogen were all in the combined group. It is lower than the conventional group [(5.06±0.31) mPa·s vs (6.10±0.33) mPa·s； (7.40±0.39) mPa·svs (9.12±0.42) mPa·s； (3.11±0.68)g/L vs (4.30±0.75)g/L] (t=15.236， 19.906， 7.797， P<0.05)； NIHSS in both groups decreased significantly after treatment (P<0.05)， and BI scores increased significantly (P<0.05). The NIHSS score of the combined group was lower than that of the conventional group (6.17±0.99)points vs (10.45±1.02) points (t=19.973， P<0.05)， and the BI score was higher than that of the conventional group (68.96±5.12) points vs (62.75±5.09) points (t=5.706， P<0.05)； the combined group had a good prognosis rate of 88.64%， significantly lower than the conventional group of 70.45% (χ2= 4.470， P<0.05). Conclusion The combination of safflor yellow and argatroban in patients with acute cerebral infarction can significantly improve the hemorheological parameters， neurological function and daily living ability， and improve the prognosis., 百拇医药(曹仕霞)
[关键词] 红花黄色素；阿加曲班；急性脑梗死；血液流变学；预后
[中图分类号] R743.3 [文献标识码] A [文章编号] 1674-0742(2018)08(a)-0113-03
Effect of Safflower Yellow Combined with Argatroban on Hemorheology and Prognosis of Patients with Acute Cerebral Infarction
CAO Shi-xia
Department of Pharmacy Outpatient， the Third People's Hospital of Jinan， Jinan， Shandong Province， 250132 China
[Abstract] Objective To investigate the effect of combined use of safflor yellow and argatroban on hemorheology in patients with acute cerebral infarction， and to observe the effect of prognosis. Methods Convenient select 88 patients with acute cerebral infarction admitted to the Third People's Hospital of Jinan City from January 2016 to September 2017 were randomly divided into conventional group (44 cases， conventional western medicine plus argatroban) and combination group (44 cases)， conventional western medicine + Argatroban + safflower yellow pigment. The changes in hemorheological indexes， changes in neurological deficit scores (NIHSS)， and daily living ability scores (BI) were compared to evaluate the prognosis. Results After treatment， the whole blood hyperviscosity， whole blood hypoviscosity， and fibrinogen were significantly decreased in the two groups (P<0.05). After treatment， the whole blood hyperviscosity， whole blood low-cut viscosity， and fibrinogen were all in the combined group. It is lower than the conventional group [(5.06±0.31) mPa·s vs (6.10±0.33) mPa·s； (7.40±0.39) mPa·svs (9.12±0.42) mPa·s； (3.11±0.68)g/L vs (4.30±0.75)g/L] (t=15.236， 19.906， 7.797， P<0.05)； NIHSS in both groups decreased significantly after treatment (P<0.05)， and BI scores increased significantly (P<0.05). The NIHSS score of the combined group was lower than that of the conventional group (6.17±0.99)points vs (10.45±1.02) points (t=19.973， P<0.05)， and the BI score was higher than that of the conventional group (68.96±5.12) points vs (62.75±5.09) points (t=5.706， P<0.05)； the combined group had a good prognosis rate of 88.64%， significantly lower than the conventional group of 70.45% (χ2= 4.470， P<0.05). Conclusion The combination of safflor yellow and argatroban in patients with acute cerebral infarction can significantly improve the hemorheological parameters， neurological function and daily living ability， and improve the prognosis., 百拇医药(曹仕霞)